Diverse presentations of transthyretin cardiac amyloidosis beyond heart failure with preserved ejection fraction

Back

HFA Premium Access

Diverse presentations of transthyretin cardiac amyloidosis beyond heart failure with preserved ejection fraction

Session: Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment

Topic: Systolic Ventricular Dysfunction

Speaker: Miss A. Achten (Maastricht, NL)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Miss Anouk Achten

Cardiovascular Research Institute Maastricht (CARIM), Maastricht (Netherlands (The))

0 follower

6 more presentations in this session

International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction

Speaker: Doctor S. Yun Viladomat (Hospitalet De Llobregat, ES)

Age- and sex-related trends in transthyretin amyloid cardiomyopathy prevalence in older patients with unexplained hypertrophic cardiomyopathy

Speaker: Professor R. Barriales-Villa (Coruna, A, ES)

SGLT2 inhibitor treatment in patients with cardiac amyloidosis

Speaker: Doctor D. Lavall (Leipzig, DE)

Prognostic importance of the 6-minute walk test in transthyretin cardiac amyloidosis

Speaker: Doctor A. Ioannou (Greater London, GB)

Cardiac manifestations as precursors to ATTR amyloidosis diagnosis: results from the multi-country OverTTuRe study

Speaker: Doctor K. Jarbrink (Gothenburg, SE)

Access the full session

Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment

Speakers: Miss A. Achten, Doctor S. Yun Viladomat, Professor R. Barriales-Villa, Doctor D. Lavall, Doctor A. Ioannou...

Access

Video

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources